Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 46 entries
Sorted by: Best Match Show Resources per page
Highlights from the 31st ECTRIMS congress - Barcelona 2015.

Multiple sclerosis (Houndmills, Basingstoke, England)

Sastre-Garriga J, Wiendl H.
PMID: 26684283
Mult Scler. 2016 Jan;22(1):7-10. doi: 10.1177/1352458515620500.

No abstract available.

Cite
Sastre-Garriga J, Wiendl H. Highlights from the 31st ECTRIMS congress - Barcelona 2015. Mult Scler. 2016;22(1):7-10doi: 10.1177/1352458515620500.
Sastre-Garriga, J., & Wiendl, H. (2016). Highlights from the 31st ECTRIMS congress - Barcelona 2015. Multiple sclerosis (Houndmills, Basingstoke, England), 22(1), 7-10. https://doi.org/10.1177/1352458515620500
Sastre-Garriga, Jaume, and Wiendl, Heinz. "Highlights from the 31st ECTRIMS congress - Barcelona 2015." Multiple sclerosis (Houndmills, Basingstoke, England) vol. 22,1 (2016): 7-10. doi: https://doi.org/10.1177/1352458515620500
Sastre-Garriga J, Wiendl H. Highlights from the 31st ECTRIMS congress - Barcelona 2015. Mult Scler. 2016 Jan;22(1):7-10. doi: 10.1177/1352458515620500. PMID: 26684283.
Copy Download .nbib Format: NLM
Optimizing treatment success in multiple sclerosis.

Journal of neurology

Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S.
PMID: 26705122
J Neurol. 2016 Jun;263(6):1053-65. doi: 10.1007/s00415-015-7986-y. Epub 2015 Dec 24.

Despite important advances in the treatment of multiple sclerosis (MS) over recent years, the introduction of several disease-modifying therapies (DMTs), the burden of progressive disability and premature mortality associated with the condition remains substantial. This burden, together with the...

Cite
Ziemssen T, Derfuss T, de Stefano N, et al. Optimizing treatment success in multiple sclerosis. J Neurol. 2015;263(6):1053-65doi: 10.1007/s00415-015-7986-y.
Ziemssen, T., Derfuss, T., de Stefano, N., Giovannoni, G., Palavra, F., Tomic, D., Vollmer, T., & Schippling, S. (2016). Optimizing treatment success in multiple sclerosis. Journal of neurology, 263(6), 1053-65. https://doi.org/10.1007/s00415-015-7986-y
Ziemssen, Tjalf, et al. "Optimizing treatment success in multiple sclerosis." Journal of neurology vol. 263,6 (2016): 1053-65. doi: https://doi.org/10.1007/s00415-015-7986-y
Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S. Optimizing treatment success in multiple sclerosis. J Neurol. 2016 Jun;263(6):1053-65. doi: 10.1007/s00415-015-7986-y. Epub 2015 Dec 24. PMID: 26705122; PMCID: PMC4893374.
Copy Download .nbib Format: NLM
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.

PloS one

Hansen K, Schüssel K, Kieble M, Werning J, Schulz M, Friis R, Pöhlau D, Schmitz N, Kugler J.
PMID: 26214805
PLoS One. 2015 Jul 27;10(7):e0133279. doi: 10.1371/journal.pone.0133279. eCollection 2015.

BACKGROUND: Long-term therapies such as disease modifying therapy for Multiple Sclerosis (MS) demand high levels of medication adherence in order to reach acceptable outcomes. The objective of this study was to describe adherence to four disease modifying drugs (DMDs)...

Cite
Hansen K, Schüssel K, Kieble M, et al. Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study. PLoS One. 2015;10(7):e0133279doi: 10.1371/journal.pone.0133279.
Hansen, K., Schüssel, K., Kieble, M., Werning, J., Schulz, M., Friis, R., Pöhlau, D., Schmitz, N., & Kugler, J. (2015). Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study. PloS one, 10(7), e0133279. https://doi.org/10.1371/journal.pone.0133279
Hansen, Kerstin, et al. "Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study." PloS one vol. 10,7 (2015): e0133279. doi: https://doi.org/10.1371/journal.pone.0133279
Hansen K, Schüssel K, Kieble M, Werning J, Schulz M, Friis R, Pöhlau D, Schmitz N, Kugler J. Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study. PLoS One. 2015 Jul 27;10(7):e0133279. doi: 10.1371/journal.pone.0133279. eCollection 2015. PMID: 26214805; PMCID: PMC4516264.
Copy Download .nbib Format: NLM
[Natalizumab treatment in multiple sclerosis].

Rinsho shinkeigaku = Clinical neurology

Tanaka M.
PMID: 26156254
Rinsho Shinkeigaku. 2015;55(8):537-43. doi: 10.5692/clinicalneurol.cn-000690. Epub 2015 Jul 07.

Multiple sclerosis is a neurodegenerative and inflammatory immune disorder in the central nervous system (CNS). Most patients show relapse-remitting clinical course. Some disease modifying medications for preventing the relapses including natalizumab (NTZ) are approved in Japan. Natalizumab (NTZ), a...

Cite
Tanaka M. [Natalizumab treatment in multiple sclerosis]. Rinsho Shinkeigaku. 2015;55(8):537-43doi: 10.5692/clinicalneurol.cn-000690.
Tanaka, M. (2015). [Natalizumab treatment in multiple sclerosis]. Rinsho shinkeigaku = Clinical neurology, 55(8), 537-43. https://doi.org/10.5692/clinicalneurol.cn-000690
Tanaka, Masami. "[Natalizumab treatment in multiple sclerosis]." Rinsho shinkeigaku = Clinical neurology vol. 55,8 (2015): 537-43. doi: https://doi.org/10.5692/clinicalneurol.cn-000690
Tanaka M. [Natalizumab treatment in multiple sclerosis]. Rinsho Shinkeigaku. 2015;55(8):537-43. doi: 10.5692/clinicalneurol.cn-000690. Epub 2015 Jul 07. Japanese. PMID: 26156254.
Copy Download .nbib Format: NLM
Indirect comparisons of treatment effects: Network meta-analyses.

Multiple sclerosis (Houndmills, Basingstoke, England)

Sormani MP.
PMID: 28273772
Mult Scler. 2017 Apr;23(4):510-512. doi: 10.1177/1352458517690272. Epub 2017 Feb 17.

Many therapeutic options are now available for patients with multiple sclerosis. While the efficacy of each drug has been assessed against placebo or, more recently, against interferon, no direct comparisons of these new therapies have been conducted in randomized...

Cite
Sormani MP. Indirect comparisons of treatment effects: Network meta-analyses. Mult Scler. 2017;23(4):510-512doi: 10.1177/1352458517690272.
Sormani, M. P. (2017). Indirect comparisons of treatment effects: Network meta-analyses. Multiple sclerosis (Houndmills, Basingstoke, England), 23(4), 510-512. https://doi.org/10.1177/1352458517690272
Sormani, Maria Pia. "Indirect comparisons of treatment effects: Network meta-analyses." Multiple sclerosis (Houndmills, Basingstoke, England) vol. 23,4 (2017): 510-512. doi: https://doi.org/10.1177/1352458517690272
Sormani MP. Indirect comparisons of treatment effects: Network meta-analyses. Mult Scler. 2017 Apr;23(4):510-512. doi: 10.1177/1352458517690272. Epub 2017 Feb 17. PMID: 28273772.
Copy Download .nbib Format: NLM
[Reflections on the outcome measures in the clinical trials of multiple sclerosis].

Zhonghua yi xue za zhi

Li HF.
PMID: 23328371
Zhonghua Yi Xue Za Zhi. 2012 Nov 20;92(43):3028-31.

No abstract available.

Cite
Li HF. [Reflections on the outcome measures in the clinical trials of multiple sclerosis]. Zhonghua Yi Xue Za Zhi. 2012;92(43):3028-31
Li, H. F. (2012). [Reflections on the outcome measures in the clinical trials of multiple sclerosis]. Zhonghua yi xue za zhi, 92(43), 3028-31.
Li, Hai-feng. "[Reflections on the outcome measures in the clinical trials of multiple sclerosis]." Zhonghua yi xue za zhi vol. 92,43 (2012): 3028-31.
Li HF. [Reflections on the outcome measures in the clinical trials of multiple sclerosis]. Zhonghua Yi Xue Za Zhi. 2012 Nov 20;92(43):3028-31. Chinese. PMID: 23328371.
Copy Download .nbib Format: NLM
A review of current and emerging therapeutic strategies in multiple sclerosis.

The American journal of managed care

Tullman MJ.
PMID: 23544717
Am J Manag Care. 2013 Feb;19(2):S21-7.

Multiple sclerosis (MS) is a chronic immune-mediated disease that potentially requires symptomatic and disease-modifying therapies. Numerous symptoms (eg, fatigue, spasticity, depression, bowel and bladder dysfunction, pain, and impaired mobility) are associated with the neurologic damage that results from MS....

Cite
Tullman MJ. A review of current and emerging therapeutic strategies in multiple sclerosis. Am J Manag Care. 2013;19(2):S21-7
Tullman, M. J. (2013). A review of current and emerging therapeutic strategies in multiple sclerosis. The American journal of managed care, 19(2), S21-7.
Tullman, Mark J. "A review of current and emerging therapeutic strategies in multiple sclerosis." The American journal of managed care vol. 19,2 (2013): S21-7.
Tullman MJ. A review of current and emerging therapeutic strategies in multiple sclerosis. Am J Manag Care. 2013 Feb;19(2):S21-7. PMID: 23544717.
Copy Download .nbib Format: NLM
Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No.

Multiple sclerosis (Houndmills, Basingstoke, England)

McMurran CE.
PMID: 34047232
Mult Scler. 2021 Jul;27(8):1162-1164. doi: 10.1177/13524585211016722. Epub 2021 May 28.

No abstract available.

Cite
McMurran CE. Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No. Mult Scler. 2021;27(8):1162-1164doi: 10.1177/13524585211016722.
McMurran, C. E. (2021). Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No. Multiple sclerosis (Houndmills, Basingstoke, England), 27(8), 1162-1164. https://doi.org/10.1177/13524585211016722
McMurran, Christopher E. "Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No." Multiple sclerosis (Houndmills, Basingstoke, England) vol. 27,8 (2021): 1162-1164. doi: https://doi.org/10.1177/13524585211016722
McMurran CE. Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No. Mult Scler. 2021 Jul;27(8):1162-1164. doi: 10.1177/13524585211016722. Epub 2021 May 28. PMID: 34047232; PMCID: PMC8226370.
Copy Download .nbib Format: NLM
Superlative use within news articles relating to therapies for multiple sclerosis.

Multiple sclerosis and related disorders

Ferrell M, Ferrell S, Ottwell R, Johnson J, Vassar M.
PMID: 33444956
Mult Scler Relat Disord. 2021 Apr;49:102736. doi: 10.1016/j.msard.2021.102736. Epub 2021 Jan 04.

BACKGROUND: Superlatives are exaggerative terms that may not accurately portray a treatment's effectiveness, safety, or availability.OBJECTIVES: The objective of this study was to evaluate the use of superlatives in news articles describing multiple sclerosis treatments.METHODS: We searched Google News...

Cite
Ferrell M, Ferrell S, Ottwell R, et al. Superlative use within news articles relating to therapies for multiple sclerosis. Mult Scler Relat Disord. 2021;49:102736doi: 10.1016/j.msard.2021.102736.
Ferrell, M., Ferrell, S., Ottwell, R., Johnson, J., & Vassar, M. (2021). Superlative use within news articles relating to therapies for multiple sclerosis. Multiple sclerosis and related disorders, 49102736. https://doi.org/10.1016/j.msard.2021.102736
Ferrell, Matthew, et al. "Superlative use within news articles relating to therapies for multiple sclerosis." Multiple sclerosis and related disorders vol. 49 (2021): 102736. doi: https://doi.org/10.1016/j.msard.2021.102736
Ferrell M, Ferrell S, Ottwell R, Johnson J, Vassar M. Superlative use within news articles relating to therapies for multiple sclerosis. Mult Scler Relat Disord. 2021 Apr;49:102736. doi: 10.1016/j.msard.2021.102736. Epub 2021 Jan 04. PMID: 33444956.
Copy Download .nbib Format: NLM
Exploring new frontiers in multiple sclerosis.

Nature reviews. Drug discovery

Kingwell K.
PMID: 34611330
Nat Rev Drug Discov. 2021 Nov;20(11):815. doi: 10.1038/d41573-021-00170-z.

No abstract available.

Cite
Kingwell K. Exploring new frontiers in multiple sclerosis. Nat Rev Drug Discov. 2021;20(11):815doi: 10.1038/d41573-021-00170-z.
Kingwell, K. (2021). Exploring new frontiers in multiple sclerosis. Nature reviews. Drug discovery, 20(11), 815. https://doi.org/10.1038/d41573-021-00170-z
Kingwell, Katie. "Exploring new frontiers in multiple sclerosis." Nature reviews. Drug discovery vol. 20,11 (2021): 815. doi: https://doi.org/10.1038/d41573-021-00170-z
Kingwell K. Exploring new frontiers in multiple sclerosis. Nat Rev Drug Discov. 2021 Nov;20(11):815. doi: 10.1038/d41573-021-00170-z. PMID: 34611330.
Copy Download .nbib Format: NLM
Inflammation as a Target for Epilepsy Therapy: The Case of Natalizumab.

Neurology

Miller JW.
PMID: 34521688
Neurology. 2021 Nov 02;97(18):845-846. doi: 10.1212/WNL.0000000000012768. Epub 2021 Sep 14.

No abstract available.

Cite
Miller JW. Inflammation as a Target for Epilepsy Therapy: The Case of Natalizumab. Neurology. 2021;97(18):845-846doi: 10.1212/WNL.0000000000012768.
Miller, J. W. (2021). Inflammation as a Target for Epilepsy Therapy: The Case of Natalizumab. Neurology, 97(18), 845-846. https://doi.org/10.1212/WNL.0000000000012768
Miller, John W. "Inflammation as a Target for Epilepsy Therapy: The Case of Natalizumab." Neurology vol. 97,18 (2021): 845-846. doi: https://doi.org/10.1212/WNL.0000000000012768
Miller JW. Inflammation as a Target for Epilepsy Therapy: The Case of Natalizumab. Neurology. 2021 Nov 02;97(18):845-846. doi: 10.1212/WNL.0000000000012768. Epub 2021 Sep 14. PMID: 34521688.
Copy Download .nbib Format: NLM
[The BCTRIMS Expanded Consensus on treatment of multiple sclerosis: III. Evidence and recommendation-based guidelines].

Arquivos de neuro-psiquiatria

Lana-Peixoto MA, Callegaro D, Moreira MA, Campos GB, Marchiori PE, Gabbai AA, Bacheschi LA, Arruda WO, Gama PD, Melo AS, Rocha FC, Lino AM, Ferreira ML, Ataide L.
PMID: 12364967
Arq Neuropsiquiatr. 2002 Sep;60(3):881-6.

There has been unprecedented advances in knowledge of multiple sclerosis (MS) in the last few years. A new set of criteria for its diagnosis and a bunch of recent clinical trials with disease-modifying agents (DMA) have been published. All...

Cite
Lana-Peixoto MA, Callegaro D, Moreira MA, et al. Consenso expandido do BCTRIMS para o tratamento da esclerose múltipla: III. Diretrizes baseadas em evidências e recomendações. [The BCTRIMS Expanded Consensus on treatment of multiple sclerosis: III. Evidence and recommendation-based guidelines]. Arq Neuropsiquiatr. 2002;60(3):881-6
Lana-Peixoto, M. A., Callegaro, D., Moreira, M. A., Campos, G. B., Marchiori, P. E., Gabbai, A. A., Bacheschi, L. A., Arruda, W. O., Gama, P. D., Melo, A. S., Rocha, F. C., Lino, A. M., Ferreira, M. L., Ataide, L. (2002). Consenso expandido do BCTRIMS para o tratamento da esclerose múltipla: III. Diretrizes baseadas em evidências e recomendações. [The BCTRIMS Expanded Consensus on treatment of multiple sclerosis: III. Evidence and recommendation-based guidelines]. Arquivos de neuro-psiquiatria, 60(3), 881-6.
Lana-Peixoto, Marco Aurélio, et al. "Consenso expandido do BCTRIMS para o tratamento da esclerose múltipla: III. Diretrizes baseadas em evidências e recomendações." [The BCTRIMS Expanded Consensus on treatment of multiple sclerosis: III. Evidence and recommendation-based guidelines]. Arquivos de neuro-psiquiatria vol. 60,3 (2002): 881-6.
Lana-Peixoto MA, Callegaro D, Moreira MA, Campos GB, Marchiori PE, Gabbai AA, Bacheschi LA, Arruda WO, Gama PD, Melo AS, Rocha FC, Lino AM, Ferreira ML, Ataide L. Consenso expandido do BCTRIMS para o tratamento da esclerose múltipla: III. Diretrizes baseadas em evidências e recomendações. [The BCTRIMS Expanded Consensus on treatment of multiple sclerosis: III. Evidence and recommendation-based guidelines]. Arq Neuropsiquiatr. 2002 Sep;60(3):881-6. Portuguese. PMID: 12364967.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 46 entries